Progress in Gynecologic Cancers with Antibody Drug Conjugates
Objective of evaluate: This text supplies a complete evaluate of antibody-drug conjugates (ADCs) beneath investigation in gynecologic cancers. The construction and performance of ADCs are reviewed with a deal with medical profit in addition to toxicity profiles.
Latest findings: A number of ADCs with varied goal antigens have been investigated in ovarian, cervical, and endometrial most cancers. ADCs have constantly demonstrated favorable security/tolerability profiles each as monotherapy and together remedy. In ovarian most cancers, response charges have ranged from 9 to 46% for monotherapy with response charges as excessive as 83% together remedy. In sufferers with cervical most cancers with progressive illness regardless of doublet remedy and bevacizumab, response charges as excessive as 24% have been noticed. ADCs characterize a quickly evolving area of focused remedy which have demonstrated notable medical profit each as monotherapy but additionally together remedy with an general favorable toxicity profile. With continued refinement of the goal biomarkers utilized, improved medical profit is more likely to be noticed.
Low seroprevalence of SARS-CoV-2 antibodies in a liver transplant cohort
Stable organ transplant recipients would possibly be at larger threat for acquisition and mortality on account of SARS-CoV-2. There isn’t a knowledge concerning SARS-CoV-2 seroprevalence amongst liver transplant (LT) recipients, and whether or not it’s totally different from that of the final inhabitants or different immunosuppressed teams. We evaluated the prevalence of IgG SARS-CoV-2 antibodies amongst LT recipients to estimate the frequency of asymptomatic SARS-CoV-2 an infection utilizing serological assays in our outpatient clinic. We performed a cross-sectional evaluation from Could 10th to October 26th 2020 of all grownup (>18 years) LT recipients that underwent a routine laboratory check for the outpatient clinic follow-up on the Hospital Universitari Vall d’Hebron (Barcelona) during which we included serological testing for SARS-CoV-2. 9 out of 294 LT recipients (3.1%) examined optimistic for anti-SARS-CoV-2 IgG antibodies.
5 of them (55.5%) had suffered clinically symptomatic SARS-CoV2 an infection confirmed by RT-PCR, 4 (44.4%) had offered suitable signs however with out microbiological affirmation and just one affected person (1/9, 11.1%) examined optimistic with none earlier symptom. SARS-CoV-2 seroprevalence amongst LT recipients in an space extremely affected by the pandemic is decrease than within the basic inhabitants in the identical space. These outcomes render the potential of asymptomatic an infection in LT recipients not possible.
Novel antibody cocktail concentrating on Guess v 1 quickly and sustainably treats birch allergy signs in a Part 1 examine
Background: The efficacy of an allergen-specific IgG cocktail to deal with cat allergy means that allergen-specific IgG could also be a significant protecting mechanism elicited by allergen immunotherapy.
Goal: Extending these findings, we examined a Guess v 1-specific antibody cocktail in birch-allergic topics.
Strategies: Part 1, randomized, double-blind, examine: Half-A, ascending doses of Guess v 1-specific antibody cocktail “REGN5713/14/15” (150-900 mg) in 32 wholesome adults; Half-B, single subcutaneous 900 mg dose or placebo in 64 birch-allergic topics. Complete nasal symptom rating (TNSS) response to titrated birch extract nasal allergen problem (NAC) and pores and skin prick check (SPT) with birch and alder allergen have been assessed at screening and days 8, 29, 57 and 113 (SPT solely); basophil activation checks (n=26) have been performed.
Outcomes: Single dose REGN5713/14/15 considerably diminished TNSS following birch NAC relative to baseline. Variations in TNSS AUC(0-1 hr) versus placebo (day 8: -1.17, P = .001; day 29: -1.18, P = .001; day 57: -0.85, P = .024) and titration SPT with birch distinction in AUC of imply wheal diameters versus placebo (all P < .001) have been sustained for ≥2 months; comparable outcomes noticed with alder SPT. REGN5713/14/15 was well-tolerated. Basophil responsiveness to birch-related allergens was considerably decreased in REGN5713/14/15-treated topics versus placebo on days 8, 57, and 113 (all P < .01).
Conclusion: Single dose REGN5713/14/15 was effectively tolerated and offered a speedy (1 week) and sturdy (2 months) discount in allergic signs after birch allergen NAC, probably providing a brand new paradigm for the remedy of birch allergy signs.
Transfusion-induced platelet antibodies and regulatory T cells in multiply transfused sufferers
Background: Platelet transfusion refractoriness (PTR) stays a tough drawback in sufferers requiring long-term platelet supportive care. Nonetheless, there are little knowledge on the frequency of platelet antibodies in multiply transfused Chinese language sufferers. Furthermore, the connection between peripheral regulatory T cells (Tregs) and PTR stays unclear.
Strategies: We retrospectively studied the frequency of alloimmunization towards platelet antigens in sufferers receiving a number of transfusions between 2013 and 2017. Monoclonal antibody solid-phase platelet antibody check (MASPAT) kits have been used to display screen for platelet antibodies earlier than every platelet transfusion. Peripheral Tregs and CD4+ CD25+ CD127– T cells have been detected by circulate cytometry, whereas reworking progress factor-beta (TGF-β) and interleukin (IL)-17 cytokines have been detected by enzyme-linked immunosorbent assay.
Outcomes: A complete of 399 sufferers who met the inclusion standards have been enrolled for the evaluation of platelet antibodies and refractoriness. Amongst these sufferers, 10 (2.5%) have been optimistic for platelet antibodies earlier than transfusion and 47 (11.8%) grew to become antibody-positive throughout the examine interval. The variety of alloimmunized sufferers was considerably greater in sufferers with hematological illness as in contrast with different illness teams (p < 0.05). Refractoriness and alloimmunization occurred in 77 (19.3%) and 22 (28.6%) sufferers, respectively. There have been no vital variations in CD4+ , CD8+ , and CD4+ CD25+ CD127– T cell numbers and plasma ranges of TGF-β1 and IL-17 between sufferers with PTR and the management group.
Conclusions: Refractoriness was frequent in sufferers present process a number of platelet transfusions (19.3%), with alloimmunization noticed in 28.6% of sufferers. Nonetheless, Tregs in peripheral blood might not play a key position in PTR.
Younger infants exhibit strong purposeful antibody responses and restrained IFN-γ manufacturing to SARS-CoV-2
Extreme COVID-19 seems uncommon in kids. That is surprising, particularly in younger infants, who’re susceptible to extreme illness attributable to different respiratory viruses. We consider convalescent immune responses in 4 infants beneath 3 months previous with confirmed COVID-19 who offered with delicate febrile sickness, alongside their dad and mom, and grownup controls recovered from confirmed COVID-19.
Though not statistically vital, in comparison with seropositive adults, infants have excessive serum ranges of IgG and IgA to SARS-CoV-2 spike protein with corresponding purposeful skill to dam SARS-CoV-2 mobile entry. Infants additionally exhibit strong saliva anti-spike IgG and IgA responses. Spike-specific IFN-γ manufacturing by toddler peripheral blood mononuclear cells seems restrained, however the frequency of spike-specific IFN-γ and/or TNF-ɑ producing T cells is comparable between infants and adults. On principal part evaluation, toddler immune responses seem distinct from their dad and mom. Sturdy purposeful antibody responses alongside restrained IFN-γ manufacturing might assist defend infants from extreme COVID-19.
Salivary IgA antibody to malondialdehyde-acetaldehyde associates with delicate periodontal pocket depth
Goal: Oxidized epitopes reminiscent of malondialdehyde-acetaldehyde (MAA) play an important position within the development of atherosclerosis by way of activation of the humoral immune response. The precise mechanism of the affiliation between atherosclerosis and periodontal illnesses shouldn’t be totally understood. The purpose of the present examine is to judge the affiliation of oral humoral immune response to oxidized epitopes with parameters of periodontal illness.
Supplies and strategies: The Parogene cohort encompass sufferers who’ve undergone coronary angiography on account of cardiac signs. On this examine, 423 sufferers have been randomly chosen for an in depth oral examination. Salivary Immunoglobulin A to oxidized epitopes and bacterial antigens was decided by chemiluminescence immunoassay.
Outcomes: In a binary logistic regression mannequin adjusted with periodontal illness confounders, periodontal pocket depth (PPD) 4-5 mm related to salivary IgA antibodies to MAA-LDL (p = 0.034), warmth shock protein 60 of Aggregatibacter actinomycetemcomitans (p = 0.045), Porphyromonas gingivalis (p = 0.045), A. actinomycetemcomitans (p = 0.005), P. intermedia (p = 0.020), and complete IgA (p = 0.003).
Conclusions: The present examine reveals the affiliation of salivary IgA to MAA-LDL with PPD 4-5 mm in a cohort of sufferers with continual coronary artery illness. Humoral immune cross-reactivation to oxidized epitopes such MAA-LDL may partly clarify the hyperlink of periodontitis with systemic illnesses.
 anti-LIF |
|||
| YF-PA12952 | Abfrontier | 50 ug | EUR 363 |
|
Description: Mouse polyclonal to LIF |
|||
 ELISA Kit) Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-b-48Tests | Reddot Biotech | 48 Tests | EUR 555 |
Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-b-96Tests | Reddot Biotech | 96 Tests | EUR 771 |
 ELISA Kit) Canine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-c-48Tests | Reddot Biotech | 48 Tests | EUR 533 |
Canine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-c-96Tests | Reddot Biotech | 96 Tests | EUR 740 |
 ELISA Kit) Human Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 367 |
Human Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 502 |
 ELISA Kit) Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-p-48Tests | Reddot Biotech | 48 Tests | EUR 555 |
Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-p-96Tests | Reddot Biotech | 96 Tests | EUR 771 |
 ELISA Kit) Rat Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 511 |
Rat Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 709 |
Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-b-48T | DL Develop | 48T | EUR 547 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids. |
|||
Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-b-96T | DL Develop | 96T | EUR 715 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids. |
|||
Canine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-c-48T | DL Develop | 48T | EUR 527 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Canine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Canine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-c-96T | DL Develop | 96T | EUR 688 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Canine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Human Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-Hu-48T | DL Develop | 48T | EUR 380 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Human Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-Hu-96T | DL Develop | 96T | EUR 485 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-p-48T | DL Develop | 48T | EUR 547 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Porcine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids. |
|||
Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-p-96T | DL Develop | 96T | EUR 715 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Porcine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids. |
|||
Rat Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-Ra-48T | DL Develop | 48T | EUR 508 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Rat Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-Ra-96T | DL Develop | 96T | EUR 661 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-b-48Tests | Reddot Biotech | 48 Tests | EUR 580 |
Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-b-96Tests | Reddot Biotech | 96 Tests | EUR 807 |
Canine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-c-48Tests | Reddot Biotech | 48 Tests | EUR 557 |
Canine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-c-96Tests | Reddot Biotech | 96 Tests | EUR 774 |
Human Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 383 |
Human Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 525 |
Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-p-48Tests | Reddot Biotech | 48 Tests | EUR 580 |
Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-p-96Tests | Reddot Biotech | 96 Tests | EUR 807 |
Rat Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 534 |
Rat Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 742 |
 Rabbit Polyclonal antibody Anti-CRBN |
|||
| Anti-CRBN | ImmunoStep | 50 µg | EUR 349 |
 Anti-LIF Antibody |
|||
| PA1562 | BosterBio | 100ug/vial | EUR 294 |
Anti-LIF Antibody |
|||
| PB9036 | BosterBio | 100ug/vial | EUR 334 |
 Anti-LIF antibody |
|||
| STJ29846 | St John's Laboratory | 100 µl | EUR 277 |
|
Description: The protein encoded by this gene is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. |
|||
Anti-LIF Antibody |
|||
| A01400 | BosterBio | 100ug/vial | EUR 294 |
Anti-LIF antibody |
|||
| STJ96472 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to LIF. |
|||
Anti-LIF antibody |
|||
| STJ73631 | St John's Laboratory | 100 µg | EUR 359 |
 anti- LIF antibody |
|||
| FNab09804 | FN Test | 100µg | EUR 548.75 |
|
Description: Antibody raised against LIF |
|||
anti- LIF antibody |
|||
| LSMab09804 | Lifescience Market | 100 ug | EUR 386 |
 LIF, Mouse |
|||
| HY-P7084 | MedChemExpress | 50ug | EUR 533 |
 LIF, mouse |
|||
| MO16102 | Neuromics | 100 ug | EUR 675 |
 antibody) Anti-LIF (aa28-39) antibody |
|||
| STJ72919 | St John's Laboratory | 100 µg | EUR 359 |
 Polyclonal Goat anti-GST α-form |
|||
| GST-ANTI-1 | Detroit R&D | 50 uL | EUR 280 |
 Polyclonal Goat anti-GST μ-form |
|||
| GST-ANTI-2 | Detroit R&D | 50 uL | EUR 280 |
 Polyclonal Goat anti-GST p-form |
|||
| GST-ANTI-3 | Detroit R&D | 50 uL | EUR 280 |
 Recombinant Mouse LIF Protein |
|||
| R01400-1 | BosterBio | 100ug/vial | EUR 294 |
 Mouse LIF ELISA Kit |
|||
| EML0014 | Abclonal | 96Tests | EUR 521 |
 Mouse LIF shRNA Plasmid |
|||
| 20-abx971321 | Abbexa |
|
|
 LIF Antibody |
|||
| 1-CSB-PA198481 | Cusabio |
|
|
|
Description: A polyclonal antibody against LIF. Recognizes LIF from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:10000, IHC:1:25-1:100 |
|||
LIF Antibody |
|||
| 1-CSB-PA012928ESR2HU | Cusabio |
|
|
|
Description: A polyclonal antibody against LIF. Recognizes LIF from Human. This antibody is Unconjugated. Tested in the following application: ELISA |
|||
LIF Antibody |
|||
| 1-CSB-PA004761 | Cusabio |
|
|
|
Description: A polyclonal antibody against LIF. Recognizes LIF from Human. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000 |
|||
 LIF, Human |
|||
| HY-P7049 | MedChemExpress | 10ug | EUR 1600 |
 LIF, human |
|||
| MO16101 | Neuromics | 100 ug | EUR 688 |
LIF Antibody |
|||
| 36950-100ul | SAB | 100ul | EUR 252 |
LIF Antibody |
|||
| 25283-100ul | SAB | 100ul | EUR 390 |
 LIF siRNA |
|||
| 20-abx922546 | Abbexa |
|
|
LIF siRNA |
|||
| 20-abx922547 | Abbexa |
|
|
 rHu LIF |
|||
| AK9977-0005 | Akron Biotech | 5µg | Ask for price |
rHu LIF |
|||
| AK9977-0025 | Akron Biotech | 25µg | Ask for price |
rHu LIF |
|||
| AK9977-0100 | Akron Biotech | 100µg | Ask for price |
rHu LIF |
|||
| AK9977-1000 | Akron Biotech | 1mg | Ask for price |
 LIF antibody |
|||
| PAab09804 | Lifescience Market | 100 ug | EUR 386 |
LIF Antibody |
|||
| 5216-100 | Biovision | EUR 316 | |
LIF Antibody |
|||
| 5216-30T | Biovision | EUR 146 | |
 LIF protein |
|||
| 30R-2771 | Fitzgerald | 10 ug | EUR 369 |
|
Description: Purified recombinant Human LIF protein |
|||
LIF protein |
|||
| 30R-2772 | Fitzgerald | 10 ug | EUR 489 |
|
Description: Purified recombinant Mouse LIF protein |
|||
 LIF Peptide |
|||
| 6245P | ProSci | 0.05 mg | EUR 164.75 |
|
Description: (IN) LIF peptide |
|||
LIF Peptide |
|||
| 43-200P | ProSci | 0.1 mg | EUR 338 |
LIF antibody |
|||
| 70R-12299 | Fitzgerald | 100 ug | EUR 403 |
|
Description: Rabbit polyclonal LIF antibody |
|||
LIF antibody |
|||
| 70R-14100 | Fitzgerald | 100 ug | EUR 322 |
|
Description: Affinity purified Rabbit polyclonal LIF antibody |
|||
LIF antibody |
|||
| 70R-6230 | Fitzgerald | 50 ug | EUR 467 |
|
Description: Rabbit polyclonal LIF antibody |
|||
LIF antibody |
|||
| 70R-51295 | Fitzgerald | 100 ul | EUR 244 |
|
Description: Purified Polyclonal LIF antibody |
|||
LIF Antibody |
|||
| 6245-002mg | ProSci | 0.02 mg | EUR 171.82 |
|
Description: LIF Antibody: LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. LIF was initially recognized by its ability to induce terminal differentiation of myeloid leukemic cells. It is a member of the IL-6 cytokine superfamily and can be highly glycosylated. LIF signaling is transduced through the LIF-R/gp130 receptor complex, leading to the phosphorylation and activation of the JAK/STAT pathway. Recent evidence shows that LIF inhibits cardiomyogenesis in embryonic stem cells via STAT3 activation. |
|||
LIF Antibody |
|||
| 6245-01mg | ProSci | 0.1 mg | EUR 436.42 |
|
Description: LIF Antibody: LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. LIF was initially recognized by its ability to induce terminal differentiation of myeloid leukemic cells. It is a member of the IL-6 cytokine superfamily and can be highly glycosylated. LIF signaling is transduced through the LIF-R/gp130 receptor complex, leading to the phosphorylation and activation of the JAK/STAT pathway. Recent evidence shows that LIF inhibits cardiomyogenesis in embryonic stem cells via STAT3 activation. |
|||
 Mouse LIF PicoKine ELISA Kit |
|||
| EK0580 | BosterBio | 96 wells | EUR 425 |
|
Description: For quantitative detection of mouse LIF in cell culture supernates, serum and plasma (heparin, EDTA). |
|||
, mouse) Leukemia Inhibitory Factor (LIF), mouse |
|||
| PR16102 | Neuromics | 5 ug | EUR 435 |
 LIF, Mouse Recombinant , 1MIU/ml |
|||
| L4500-001 | GenDepot | 1ml | EUR 339 |
LIF, Mouse Recombinant , 1MIU/ml |
|||
| L4500-005 | GenDepot | 5x1ml | EUR 1193 |
 LIF, Mouse Recombinant , 10MIU/ml |
|||
| L4501-001 | GenDepot | 1ml | EUR 1454 |
 (OKEH04045)) LIF ELISA Kit (Mouse) (OKEH04045) |
|||
| OKEH04045 | Aviva Systems Biology | 96 Wells | EUR 544 |
|
Description: Description of target: LIF has the capacity to induce terminal differentiation in leukemic cells. Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes.;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.039 ng/mL |
|||
 (OKBB00760)) LIF ELISA Kit (Mouse) (OKBB00760) |
|||
| OKBB00760 | Aviva Systems Biology | 96 Wells | EUR 505 |
|
Description: Description of target: Leukemia inhibitory factor, or LIF, is an interleukin 6 class cytokine that affects cell growth by inhibiting differentiation. When LIF levels drop, the cells differentiate. The LIF was mapped gene to 22q11-q12.2 by Southern analysis of a series of mouse/human somatic cell hybrids and by in situ hybridization to the chromosomes of 2 normal males and some individuals with chromosomal rearrangements. The gene maps between the Philadelphia translocation BCR1 and the breakpoint of the translocation in cell line GM2324 at 22q12.2. LIF derives its name from its ability to induce the terminal differentiation of myeloid leukemic cells, thus preventing their continued growth. Other properties attributed to the cytokine include: the growth promotion and cell differentiation of different types of target cells, influence on bone metabolism, cachexia, neural development, embryogenesis and inflammation.;Species reactivity: Mouse;Application: ELISA;Assay info: ;Sensitivity: <10pg/ml |
|||
 ELISA kit for Mouse LIF |
|||
| EK5250 | SAB | 96 tests | EUR 553 |
|
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse LIF in samples from serum, plasma, tissue homogenates and other biological fluids. |
|||
 (pORF)) Lif ORF Vector (Mouse) (pORF) |
|||
| ORF049145 | ABM | 1.0 ug DNA | EUR 506 |
Lif ORF Vector (Mouse) (pORF) |
|||
| ORF049146 | ABM | 1.0 ug DNA | EUR 506 |
 Human CellExp? LIF, mouse recombinant |
|||
| 7268-10 | Biovision | EUR 370 | |
 LIF Polyclonal Antibody |
|||
| ES3837-100ul | ELK Biotech | 100ul | EUR 279 |
|
Description: A Rabbit Polyclonal antibody against LIF from Human. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
|||
LIF Polyclonal Antibody |
|||
| ES3837-50ul | ELK Biotech | 50ul | EUR 207 |
|
Description: A Rabbit Polyclonal antibody against LIF from Human. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
|||
 Polyclonal LIF Antibody |
|||
| APR00279G | Leading Biology | 0.1mg | EUR 484 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human LIF . This antibody is tested and proven to work in the following applications: |
|||
Polyclonal LIF Antibody |
|||
| APR06696G | Leading Biology | 0.1 mg | EUR 659 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human LIF . This antibody is tested and proven to work in the following applications: |
|||
LIF Polyclonal Antibody |
|||
| ABP52838-003ml | Abbkine | 0.03ml | EUR 158 |
|
Description: A polyclonal antibody for detection of LIF from Human. This LIF antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human LIF |
|||
